Article Text

Download PDFPDF
Prevalence and Progression of Chronic Kidney Disease in Adult Patients With Sickle Cell Disease
  1. Elvira O. Gosmanova, MD, FASN*,
  2. Sahar Zaidi, MD,
  3. Jim Y. Wan, PhD,
  4. Patricia E. Adams-Graves, MD
  1. From the Divisions of *Nephrology, and †Hematology, Department of Medicine, and ‡Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN.
  1. Received November 18, 2013, and in revised form March 3, 2014.
  2. Accepted for publication March 14, 2014.
  3. Reprints: Elvira O. Gosmanova, MD, FASN, 956 Court Ave, Suite B226, Memphis, TN 38103. E-mail: egosmano{at}
  4. Disclaimers: None of the authors who participated in the preparation of the article have any potential conflicts of interest.
  5. Source of funding: None. This work was not supported by any grant or funding.


Aim We evaluated the prevalence and progression of chronic kidney disease (CKD) during the 5-year period in a cohort of patients with sickle cell disease (SCD) aged 18 years and older.

Methods We studied 98 patients with SCD. Chronic kidney disease stages I through V were defined based on estimated glomerular filtration rate (eGFR), and albuminuria grades were defined based on spot urine protein-to-creatinine ratio according to the 2012 Kidney Disease Improving Global Outcomes recommendations. In patients with eGFR of greater than 60 mL/min per 1.73 m2, CKD was diagnosed if grade A2 or A3 albuminuria was present. Chronic kidney disease progression was defined as an increase in CKD stage with an additional eGFR reduction of more than 25% from baseline.

Results At baseline, 28.6% of patients had CKD. After a mean follow-up of 5.0 (SD, 0.9) years, 17 patients developed new CKD and the overall CKD prevalence increased to 41.8%. In addition, 8 patients experienced CKD progression. The following baseline variables were associated with the development and progression of CKD in univariate analysis: older age (P = 0.003), higher systolic blood pressure (BP; P = 0.003), lower eGFR (P = 0.001), higher serum creatinine (P = 0.001), and A3 albuminuria (P = 0.008). In multivariate analysis, baseline A3 albuminuria (adjusted odds ratio, 5.0; 95% confidence interval, 1.1-24.3; P = 0.048) and each 1-mm Hg increase in systolic BP (adjusted odds ratio, 1.04; 95% confidence interval, 1.0-1.07; P = 0.039) predicted CKD development and progression.

Conclusions Chronic kidney disease is common in patients with SCD and its prevalence increases with age. Several baseline modifiable and nonmodifiable factors were associated with the development and progression of CKD in patients with SCD. Strategies targeting BP control and proteinuria may be beneficial for individuals with SCD.

Key Words
  • chronic kidney disease
  • sickle cell disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.